WHO Issues Alert Over Acute Scarcity of Weight-Loss Medications

Under one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it issues its inaugural recommendations on the drugs.

With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for increased and just availability to this class of drugs.

According to forecasts, over two billion are projected to be obese by 2030 if no action is taken.

"The latest guidance recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are major hurdles to universal access to the injections that can assist patients in reducing substantial body mass, explains the organization.

Skinny Jab Shortage

Despite the present best projected outlook, the manufacturing of GLP-1 therapies could only cover around 100 million people – fewer than 10% of the global need, per the health organization.

The recommendation calls on nations and manufacturers to widen access, through strategies such as patent sharing.

Exclusive production rights on a key compound – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.

The Way Weight-Loss Jabs Function

GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost satiety so users eat less.

People typically see weight reduction after several weeks of commencing the once-weekly jabs.

Evidence suggests users may put most of the weight back on a year later of discontinuing the drug, as their typical hunger come back.

Being above a healthy weight elevates your risk for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight impacts individuals in every country and was linked to millions of deaths worldwide in 2024, as per the WHO.